Ceria Therapeutics, Inc.
4:30 PM - 4:45 PM (EDT), Tuesday, June 6, 2023 ・ Session Room 104C
Ceria Therapeutics is a preclinical biopharmaceutical company that develops drug products to treat diseases characterized by dysregulated inflammation. Our flagship products target lung diseases, including acute lung injury and acute respiratory distress syndrome. The company is also developing other products to treat unmet medical needs including inflammatory bowel disease, non-healing wounds, and pressure ulcers, collectively representing >$20B US market opportunity. The company has secured $7.6M for product development and received ~$10M in R&D grants. Ceria is seeking committed investors to expand capabilities and support clinical development. The company's products will compete indirectly with specialty pharmaceutical companies and medical device companies that serve the critical care and wound care markets. Several products in development for ALI/ARDS may also come to market over the next few years and represent potential direct competitors.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
AZ
Company HQ Country:
United States
Year Founded:
2019
Main Therapeutic Focus:
Respiratory
Lead Product in Development:
CTX-002 For treatment of acute lung injuries and acute respiratory distress syndrome
Development Phase of Primary Product:
Pre-Clinical
Number Of Unlicensed Products (For Which You Are Seeking Partners):
CTX-002-IT for acute respiratory distress syndrome
CTX-002-IT for acute lung injuries
CTX-003 for inflammatory bowel disease
CTX-001 / CTX-004 non-healing wounds and diabetic foot ulcers
CTX-005 for pressure ulcers
Speaker
